{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:22:24Z","timestamp":1773933744215,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Obsessive\u2013compulsive symptoms (OCS) frequently manifest in individuals with schizophrenia, affecting their prognosis and quality of life. The etiology of OCS in schizophrenia is complex, with theories ranging from subtype-specific manifestations to pharmacological influences. Notably, clozapine has been associated with a higher prevalence of OCS. However, the clinical factors influencing clozapine-induced OCS remain unclear. This cross-sectional study recruited individuals diagnosed with schizophrenia who were using clozapine, as well as a comparison group of individuals diagnosed with schizophrenia who were using other second-generation antipsychotics (SGA). Clinical assessments included OCS which were quantified using the Obsessive\u2013Compulsive Inventory-Revised (OCI-R). 189 Participants were recruited, of whom 129 were taking clozapine and 60 other atypical antipsychotics. Statistical analyses, including moderated regression modeling, identified clinical factors influencing OCS occurrence. Clozapine users exhibited significantly higher OCI-R scores compared to non-clozapine users (p\u2009=\u20090.001). Moderated regression analysis revealed a moderating effect of negative symptom severity, indicating that when negative symptoms increased, the difference in OCI-R scores between clozapine and non-clozapine groups decreased. Other factors like duration of illness, medication duration, and psychopathology severity did not significantly moderate the group differences in OCI-R scores. As negative symptoms worsened, the impact of clozapine on OCS lessened, a pattern not seen with other antipsychotics. This suggests that clozapine\u2019s effect on OCS is specific and influenced by different mechanisms. The study recommends screening for OCS in patients with mild negative symptoms and further research into biological markers to better understand clozapine-induced OCS.<\/jats:p>","DOI":"10.1007\/s00406-025-02021-z","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T10:31:28Z","timestamp":1747391488000},"page":"991-999","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Negative symptomatology and clozapine-induced obsessive\u2013compulsive symptoms: a cross-sectional analysis"],"prefix":"10.1007","volume":"276","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-8388","authenticated-orcid":false,"given":"Phillip","family":"Kleymann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Morgenroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Gutwinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Bermpohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alkomiet","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Okhuijsen-Pfeifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurjen J.","family":"Luykx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marte Z.","family":"van der Horst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Oviedo-Salcedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Schreiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"2","key":"2021_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.schres.2013.10.033","volume":"152","author":"M Swets","year":"2014","unstructured":"Swets M, Dekker J, van Emmerik-van OK, Smid GE, Smit F, de Haan L et al (2014) The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. Schizophr Res 152(2):458\u2013468","journal-title":"Schizophr Res"},{"issue":"8","key":"2021_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11920-019-1051-y","volume":"21","author":"C Tezenas du Montcel","year":"2019","unstructured":"Tezenas du Montcel C, Pelissolo A, Sch\u00fcrhoff F, Pignon B (2019) Obsessive-compulsive symptoms in schizophrenia: an up-to-date review of literature. Curr Psychiatry Rep. 21(8):64","journal-title":"Curr Psychiatry Rep."},{"issue":"1","key":"2021_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1471-244X-13-156","volume":"13","author":"K Hagen","year":"2013","unstructured":"Hagen K, Hansen B, Joa I, Larsen TK (2013) Prevalence and clinical characteristics of patients with obsessive-compulsive disorder in first-episode psychosis. BMC Psychiatry 13(1):156","journal-title":"BMC Psychiatry"},{"issue":"1","key":"2021_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.schres.2006.09.023","volume":"90","author":"L Sevincok","year":"2007","unstructured":"Sevincok L, Akoglu A, Kokcu F (2007) Suicidality in schizophrenic patients with and without obsessive-compulsive disorder. Schizophr Res 90(1):198\u2013202","journal-title":"Schizophr Res"},{"issue":"5","key":"2021_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","volume":"209","author":"D Siskind","year":"2016","unstructured":"Siskind D, McCartney L, Goldschlager R, Kisely S (2016) Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 209(5):385\u201392","journal-title":"Br J Psychiatry."},{"issue":"8","key":"2021_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1017\/S1092852900020381","volume":"14","author":"L de Haan","year":"2009","unstructured":"de Haan L, Dudek-Hodge C, Verhoeven Y, Denys D (2009) Prevalence of psychotic disorders in patients with obsessive-compulsive disorder. CNS Spectr 14(8):415\u2013417","journal-title":"CNS Spectr"},{"issue":"5","key":"2021_CR7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.comppsych.2014.03.016","volume":"55","author":"A Fr\u00edas","year":"2014","unstructured":"Fr\u00edas A, Palma C, Farriols N, Salvador A, Bonet J, Bern\u00e1ldez I (2014) Psychopathology and quality of life among patients with comorbidity between schizophrenia spectrum disorder and obsessive-compulsive disorder: no evidence for a \u201cschizo-obsessive\u201d subtype. Compr Psychiatry 55(5):1165\u20131173","journal-title":"Compr Psychiatry"},{"issue":"1\u20133","key":"2021_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.schres.2012.06.033","volume":"140","author":"AR Docherty","year":"2012","unstructured":"Docherty AR, Coleman MJ, Tu X, Deutsch CK, Mendell NR, Levy DL (2012) Comparison of putative intermediate phenotypes in schizophrenia patients with and without obsessive-compulsive disorder: examining evidence for the schizo-obsessive subtype. Schizophr Res 140(1\u20133):83\u201386","journal-title":"Schizophr Res"},{"issue":"3","key":"2021_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1139\/jpn.0527","volume":"30","author":"A Bottas","year":"2005","unstructured":"Bottas A, Cooke RG, Richter MA (2005) Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? J Psychiatry Neurosci 30(3):187\u2013193","journal-title":"J Psychiatry Neurosci"},{"issue":"5","key":"2021_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.comppsych.2011.08.009","volume":"53","author":"M Poyurovsky","year":"2012","unstructured":"Poyurovsky M, Zohar J, Glick I, Koran LM, Weizman R, Tandon R et al (2012) Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. Compr Psychiatry 53(5):480\u2013483","journal-title":"Compr Psychiatry"},{"issue":"6","key":"2021_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4088\/JCP.v60n0603","volume":"60","author":"L de Haan","year":"1999","unstructured":"de Haan L, Linszen DH, Gorsira R (1999) Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 60(6):364\u2013365","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"2021_CR12","first-page":"439","volume":"53","author":"RW Baker","year":"1992","unstructured":"Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR (1992) Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 53(12):439\u2013442","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"2021_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11920-014-0510-8","volume":"16","author":"TM Fonseka","year":"2014","unstructured":"Fonseka TM, Richter MA, M\u00fcller DJ (2014) Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature. Curr Psychiatry Rep 16(11):510","journal-title":"Curr Psychiatry Rep"},{"issue":"1","key":"2021_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/157015912799362724","volume":"10","author":"F Schirmbeck","year":"2012","unstructured":"Schirmbeck F, Zink M (2012) Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol 10(1):88\u201395","journal-title":"Curr Neuropharmacol"},{"issue":"7","key":"2021_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Meht\u00e4l\u00e4 J, Hoti F, Jedenius E et al (2017) Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiat 74(7):686\u2013693","journal-title":"JAMA Psychiat"},{"issue":"2","key":"2021_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S2215-0366(23)00366-8","volume":"11","author":"O Efthimiou","year":"2024","unstructured":"Efthimiou O, Taipale H, Radua J, Schneider-Thoma J, Pinz\u00f3n-Espinosa J, Ortu\u00f1o M et al (2024) Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data. Lancet Psychiatry 11(2):102\u2013111","journal-title":"Lancet Psychiatry"},{"key":"2021_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-59380-6","volume-title":"S3-leitlinie schizophrenie","author":"W Gaebel","year":"2019","unstructured":"Gaebel W, Hasan A, Falkai P (2019) S3-leitlinie schizophrenie. Springer-Verlag, New York"},{"issue":"6","key":"2021_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","volume":"201","author":"OD Howes","year":"2012","unstructured":"Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D (2012) Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 201(6):481\u2013485","journal-title":"Br J Psychiatry"},{"key":"2021_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fphar.2013.00099","volume":"4","author":"F Schirmbeck","year":"2013","unstructured":"Schirmbeck F, Zink M (2013) Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front Pharmacol 4:99","journal-title":"Front Pharmacol"},{"issue":"1","key":"2021_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00406-023-01593-y","volume":"274","author":"CL Morgenroth","year":"2023","unstructured":"Morgenroth CL, Kleymann P, Ripke S, Awasthi S, Wagner E, Oviedo-Salcedo T et al (2023) Polygenetic risk scores and phenotypic constellations of obsessive-compulsive disorder in clozapine-treated schizophrenia. Eur Arch Psychiatry Clin Neurosci. 274(1):181\u2013193","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"issue":"11","key":"2021_CR21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1055\/s-0042-116227","volume":"84","author":"S Schreiter","year":"2016","unstructured":"Schreiter S, Hasan A, Majic T, Wullschleger A, Schouler-Ocak M, Bermpohl F et al (2016) Obsessive-compulsive symptoms in a sample of patients with chronic schizophrenia under clozapine treatment. Fortschr Neurol Psychiatr 84(11):675\u2013681","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"16","key":"2021_CR22","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1017\/S003329171800017X","volume":"48","author":"E Fernandez-Egea","year":"2018","unstructured":"Fernandez-Egea E, Worbe Y, Bernardo M, Robbins TW (2018) Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. Psychol Med 48(16):2668\u20132675","journal-title":"Psychol Med"},{"issue":"11","key":"2021_CR23","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1017\/S0033291711000419","volume":"41","author":"F Schirmbeck","year":"2011","unstructured":"Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M (2011) Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med 41(11):2361\u20132373","journal-title":"Psychol Med"},{"issue":"8","key":"2021_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.euroneuro.2019.06.006","volume":"29","author":"M Biria","year":"2019","unstructured":"Biria M, Huang FX, Worbe Y, Fineberg NA, Robbins TW, Fernandez-Egea E (2019) A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD. Eur Neuropsychopharmacol 29(8):905\u2013913","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"2021_CR25","first-page":"155","volume":"19","author":"M Coskun","year":"2009","unstructured":"Coskun M, Zoroglu S (2009) Clozapine induced obsessions treated with sertraline in an adolescent with schizophrenia. Klinik Psikofarmakoloji Bulteni 19(2):155","journal-title":"Klinik Psikofarmakoloji Bulteni"},{"issue":"4","key":"2021_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/0269881112463470","volume":"27","author":"F Schirmbeck","year":"2013","unstructured":"Schirmbeck F, Rausch F, Englisch S, Eifler S, Esslinger C, Meyer-Lindenberg A et al (2013) Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study. J Psychopharmacol 27(4):349\u2013357","journal-title":"J Psychopharmacol"},{"key":"2021_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113665","volume":"296","author":"G G\u00fcrcan","year":"2021","unstructured":"G\u00fcrcan G, \u015eenol \u015eH, Ya\u011fc\u0131o\u011flu AEA, Ertu\u011frul A (2021) Clinical risk factors, phenomenology and the impact of clozapine induced obsessive compulsive symptoms. Psychiatry Res 296:113665","journal-title":"Psychiatry Res"},{"issue":"3","key":"2021_CR28","first-page":"219","volume":"56","author":"A Kokurcan","year":"2019","unstructured":"Kokurcan A (2019) Comparison of clinical characteristics between the patients with schizophrenia on clozapine treatment with those taking combination of long-acting injectable and oral antipsychotics. Noro Psikiyatr Ars 56(3):219\u2013223","journal-title":"Noro Psikiyatr Ars"},{"issue":"1","key":"2021_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41398-022-01884-3","volume":"12","author":"C Okhuijsen-Pfeifer","year":"2022","unstructured":"Okhuijsen-Pfeifer C, van der Horst MZ, Bousman CA, Lin B, van Eijk KR, Ripke S et al (2022) Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders. Transl Psychiatry 12(1):145","journal-title":"Transl Psychiatry"},{"issue":"Suppl 1","key":"2021_CR30","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, Davis JM (2016) Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 42(Suppl 1):S90-4","journal-title":"Schizophr Bull."},{"issue":"9\u201310","key":"2021_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1055\/s-2007-970894","volume":"57","author":"S G\u00f6nner","year":"2007","unstructured":"G\u00f6nner S, Leonhart R, Ecker W (2007) The German version of the obsessive-compulsive inventory-revised: a brief self-report measure for the multidimensional assessment of obsessive-compulsive symptoms. Psychother Psychosom Med Psychol 57(9\u201310):395\u2013404","journal-title":"Psychother Psychosom Med Psychol"},{"key":"2021_CR32","doi-asserted-by":"crossref","unstructured":"Guy W (1976) ECDEU assessment manual for psychopharmacology: US Department of Health, Education, and Welfare, Public Health Service.","DOI":"10.1037\/e591322011-001"},{"issue":"10","key":"2021_CR33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1001\/jama.1994.03520100096046","volume":"272","author":"CC Bell","year":"1994","unstructured":"Bell CC (1994) DSM-IV: diagnostic and statistical manual of mental disorders. JAMA 272(10):828\u2013829","journal-title":"JAMA"},{"issue":"2","key":"2021_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261\u2013276","journal-title":"Schizophr Bull"},{"issue":"4","key":"2021_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","volume":"3","author":"D Addington","year":"1990","unstructured":"Addington D, Addington J, Schissel B (1990) A depression rating scale for schizophrenics. Schizophr Res 3(4):247\u2013251","journal-title":"Schizophr Res"},{"issue":"9","key":"2021_CR36","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton TF, Kozlowski LT, Frecker RC, Fagerstr\u00f6m KO (1991) The Fagerstr\u00f6m test for nicotine dependence: a revision of the Fagerstr\u00f6m Tolerance Questionnaire. Br J Addict 86(9):1119\u20131127","journal-title":"Br J Addict"},{"key":"2021_CR37","volume-title":"Manual of directions and scoring","author":"AIT Battery","year":"1944","unstructured":"Battery AIT (1944) Manual of directions and scoring. War Department, Adjutant General\u2019s Office, Washington"},{"issue":"1","key":"2021_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1024\/1016-264X\/a000060","volume":"23","author":"K Rodewald","year":"2012","unstructured":"Rodewald K, Bartolovic M, Debelak R, Aschenbrenner S, Weisbrod M, Roesch-Ely D (2012) Eine Normierungsstudie eines modifizierten trail making tests im deutschsprachigen Raum. Z Neuropsychol 23(1):37\u201348","journal-title":"Z Neuropsychol"},{"key":"2021_CR39","doi-asserted-by":"publisher","DOI":"10.1017\/SJP.2021.46","volume":"24","author":"JJ Igartua","year":"2021","unstructured":"Igartua JJ, Hayes AF (2021) Mediation, moderation, and conditional process analysis: concepts, computations, and some common confusions. Span J Psychol 24:e49","journal-title":"Span J Psychol"},{"issue":"8","key":"2021_CR40","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2174\/1570159X16666180813155017","volume":"17","author":"A Del Casale","year":"2019","unstructured":"Del Casale A, Sorice S, Padovano A, Simmaco M, Ferracuti S, Lamis DA et al (2019) Psychopharmacological treatment of Obsessive-Compulsive Disorder (OCD). Curr Neuropharmacol 17(8):710\u2013736","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"2021_CR41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/(SICI)1098-2396(199612)24:4<349::AID-SYN5>3.0.CO;2-D","volume":"24","author":"CR Ashby Jr","year":"1996","unstructured":"Ashby CR Jr, Wang RY (1996) Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24(4):349\u2013394","journal-title":"Synapse"},{"issue":"3","key":"2021_CR42","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1007\/s13311-017-0552-9","volume":"14","author":"FC Nucifora","year":"2017","unstructured":"Nucifora FC, Mihaljevic M, Lee BJ, Sawa A (2017) Clozapine as a model for antipsychotic development. Neurotherapeutics 14(3):750\u2013761","journal-title":"Neurotherapeutics"},{"issue":"3","key":"2021_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0893-133X(95)00068-O","volume":"13","author":"N Brunello","year":"1995","unstructured":"Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13(3):177\u2013213","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"2021_CR44","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","volume":"27","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors\u202f: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27(7):1159\u20131172","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2021_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.psychres.2016.09.031","volume":"246","author":"D Grillault Laroche","year":"2016","unstructured":"Grillault Laroche D, Gaillard A (2016) Induced Obsessive Compulsive Symptoms (OCS) in schizophrenia patients under Atypical 2 Antipsychotics (AAPs): review and hypotheses. Psychiatry Res 246:119\u2013128","journal-title":"Psychiatry Res"},{"key":"2021_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neubiorev.2020.06.004","volume":"116","author":"I B\u00e8gue","year":"2020","unstructured":"B\u00e8gue I, Kaiser S, Kirschner M (2020) Pathophysiology of negative symptom dimensions of schizophrenia\u2014current developments and implications for treatment. Neurosci Biobehav Rev 116:74\u201388","journal-title":"Neurosci Biobehav Rev"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-025-02021-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-025-02021-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-025-02021-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:02:52Z","timestamp":1773925372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-025-02021-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2021"],"URL":"https:\/\/doi.org\/10.1007\/s00406-025-02021-z","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}